June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
AAV Gene Therapy in a Canine Model of MPS1 Prevents and Reverses Corneal Blindness
Author Affiliations & Notes
  • Matthew Hirsch
    Ophthalmology, University of North Carolina, Chapel Hill, North Carolina, United States
    Gene Therapy Center, University of North Carolina, Chapel Hill , North Carolina, United States
  • Brian C Gilger
    North Carolina State University, Raleigh, North Carolina, United States
  • Telmo Llanga
    Ophthalmology, University of North Carolina, Chapel Hill, North Carolina, United States
  • Richard Davis
    Ophthalmology, University of North Carolina, Chapel Hill, North Carolina, United States
  • Joanne Kurtzberg
    Duke University, Durham, North Carolina, United States
  • Richard J Samulski
    Gene Therapy Center, University of North Carolina, Chapel Hill , North Carolina, United States
  • Keiko Miyadera
    University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Footnotes
    Commercial Relationships   Matthew Hirsch, University of North Carolina (P); Brian Gilger, None; Telmo Llanga, None; Richard Davis, None; Joanne Kurtzberg, None; Richard Samulski, University of North Carolina (P); Keiko Miyadera, None
  • Footnotes
    Support  RO1AI072176-06A1, NCTRACs, Funding was also provided in part through a departmental Unrestricted Grant from Research to Prevent Blindness, New York, NY, USA
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 4480. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Matthew Hirsch, Brian C Gilger, Telmo Llanga, Richard Davis, Joanne Kurtzberg, Richard J Samulski, Keiko Miyadera; AAV Gene Therapy in a Canine Model of MPS1 Prevents and Reverses Corneal Blindness. Invest. Ophthalmol. Vis. Sci. 2017;58(8):4480.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Mucopolysacharidosis type 1 (MPS1) is a devastating lysosomal storage disease that can be lethal in the first decade of life. Bone marrow transplantation has proven effective at prolonging life by decades, however, the patient’s quality of life is compromised due to non-lethal MPS1 manifestations including blindness. In particular, approximately 90% of MPS1 children present corneal opacity with about 50% of cases causing complete vision loss. There is no effective treatment for MPS1 corneal blindness, which is the deficit we seek to address in this work using a viral based gene addition strategy. This technology is envisioned as complementary therapeutic to approaches such as cell therapy that address systemic MPS1 disease symptoms.

Methods : A codon optimized IDUA cassette was packaged in a chimeric AAV capsid identified efficient for cornea transduction. Previous evaluations in human corneas ex vivo demonstrated supraphysiological IDUA activity and safety following intrastromal injection of AAV8G9-optIDUA. These optimistic data warranted an efficacy study in naturally occurring MPS1 canines that also suffer from corneal clouding. Three canines with advanced (13 m.o.) and one with early (9 m.o.) corneal diseases were administered AAV8G9-GFP (negative control) in one eye and AAV8G9-optIDUA in the contralateral eye via cornea stromal injections. These canines have been monitored by slit lamp biomicroscopy and corneal imaging currently out 14 weeks post-injections.

Results : Corneal clearing, encompassing both the actual cloudy storage disease and regression of associated vascularization was apparent as early as 1 week and near complete disease reversal is now evident 13 weeks in all corneas injected with AAV-8G9-optIDUA in the symptomatic cohort. In the younger animal with the early disease, corneal disease progression continued in the control eye while the AAV8G9-optIDUA injected cornea demonstrated clearance of microscopic storage materials and did not develop vascularization. No adverse effect was observed specific to the injection or either of the transgenes, except for transient reversible corneal edemas that developed in each eye of one animal at 6 and 10 weeks post injection.

Conclusions : The collective data of a corneal gene addition strategy using AAV vectors for MPS1 blindness demonstrate safety and efficacy and lend support for the evaluation of this technology in MPS1 children.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×